111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (e+)" rating restated by research analysts at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.
111 Stock Down 0.4%
Shares of YI stock traded down $0.03 during mid-day trading on Friday, reaching $7.11. The stock had a trading volume of 6,190 shares, compared to its average volume of 24,886. 111 has a one year low of $4.15 and a one year high of $12.90. The firm has a market cap of $61.43 million, a PE ratio of -11.11 and a beta of 0.44. The firm's 50 day simple moving average is $7.96 and its 200 day simple moving average is $7.54.
111 (NASDAQ:YI - Get Free Report) last issued its earnings results on Thursday, June 19th. The company reported ($0.20) EPS for the quarter. The company had revenue of $486.35 million during the quarter.
Institutional Investors Weigh In On 111
A number of hedge funds have recently made changes to their positions in the company. Napean Trading & Investment Co Singapore PTE Ltd acquired a new position in shares of 111 in the 4th quarter worth approximately $245,000. JPMorgan Chase & Co. grew its holdings in shares of 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after purchasing an additional 305,339 shares during the last quarter. FIL Ltd bought a new stake in shares of 111 during the fourth quarter worth $450,000. Deuterium Capital Management LLC bought a new position in shares of 111 in the first quarter valued at about $81,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in 111 in the 1st quarter valued at about $92,000. Institutional investors and hedge funds own 21.32% of the company's stock.
About 111
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Recommended Stories
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
